Proposal for a Regulation of the European Parliament and of the Council on medical devices and Directive Amending 2001 / 83 / EC, Regulation (EC) No 178 / 2002 and Regulation (EC) No 1223 / 2009
- Published: Friday August 21 2015 10: 37
This Regulation Establishes lays down rulesconcernant the Placing on the market, making available put on the market orthings Into Service of medical devices and accessories to medical devices for human use in the Union.This regulation aussi Applies to clinical investigations Conducted medical devices are in the Union.
- Published: Friday August 21 2015 09: 37
Ce document est the seventh annual report of the Pharmacovigilance Inspectors Working Group. The IWG PhV1 has-been Established by the European Medicines Agency (hereinafter "the Agency") Within the scope of Article 57 (1) (i) of Regulation (EC) No 726 / 2004. Following a report on the first year of operation the IWG PhV Mandate Was endorsed by the Heads of Medicines Agencies is 18-19 May 2009 and by the Agency's Management Board on October 1 2009, thereby Formally Establishing the PhV IWG.
- Published: Thursday July 30 2015 08: 37
This guidance supersedes the draft of the Sami Name That published on February 19, 2014 (EN 79 16 9467) and replaces the 2000 draft guidance for industry on Analytical Procedures and Methods Validationand the 1987 Guidelines for Submitting Samples and Analytical Data for MethodsValidation. It provides recommendations on how you, the application covered, can submit analytical procedures4 and validation methods5 data carrier to the documentation of the identity, strength, quality, purity, and potency of drug substances and drug products.
- Published: Friday August 21 2015 08: 37
This guidance Describes the Center for Drug Evaluation and Research's (CDER's) current thinking on Appropriate Development Plans for botanical drugs to be Submitted in new drug applications (NDAs) and specific recommendations on Submitting investigational new drug applications (INDs) in Support of future NDA submissions for botanical drugs. In addition, this guidance provides information on the general over-the-counter (OTC) drug monograph system for botanical drugs. ALTHOUGH this guidance Does not INTEND to Provide recommendations specific to botanical drugs to be Marketed under biologics license applications (BLAs) Many scientific principles Described in this guidance apply to May aussi thesis products.
- Published: Thursday July 30 2015 08: 36
Quality metrics are used Throughout the pharmaceutical industry to monitor quality control systems and processes and drive continuous improvement efforts in drug manufacturing. These metrics can be used by FDA aussi: to help Develop compliance and inspection policies and practices, Such As risk-based inspection scheduling of drug manufacturers; to Improve the Agency's Ability to predict, and The Therefore, Mitigate Possibly, future drug Shortages; and to encourage the pharmaceutical industry to Implement state-of-the-art, innovative quality management systems for pharmaceutical manufacturing.